Day: February 5, 2025

SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held in conjunction with this year’s Super Bowl celebrations in New Orleans on February 8, 2025. The event will focus on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment. Dr. Kelly, a leading expert in neurology and concussion care, joins an esteemed lineup of thought leaders to discuss the long-term impact of TBIs, groundbreaking advances in treatment, and strategies for prevention. His expertise...

GRAND CAYMAN, Cayman Islands, Feb. 05, 2025 (GLOBE NEWSWIRE) — Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), together with its subsidiary SurancePlus, is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, today announced it has selected Coinbase Prime to facilitate the purchase and secure custody of Bitcoin and Ethereum along with potentially other cryptocurrencies as a treasury reserve asset. Jay Madhu, CEO of Oxbridge, commented, “Our collaboration with Coinbase underscores our commitment to integrating cutting-edge blockchain solutions into our financial framework. By working with Coinbase, we are confident in our ability to securely manage...

FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows: Date: Wednesday, February 12, 2025Time: 12:00 PM Eastern TimeWebcast: Click HERE A replay of the corporate presentation will be available on the Events section of the company’s investor relations website. About Cellectar Biosciences, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment...

Stellantis to Announce Full Year 2024 Results on February 26 AMSTERDAM, February 5, 2025 – Stellantis N.V. announced today that its Full Year 2024 Results will be released on Wednesday, February 26, 2025. A live webcast and conference call of the Full Year 2024 Results will begin at 2:00 p.m. CET / 8:00 a.m. EST on Wednesday, February 26, 2025. The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website at www.stellantis.com at approximately 8:00 a.m. CET / 2:00 a.m. EST on Wednesday, February 26, 2025. Details for accessing this presentation are available under the Investors section of the Stellantis corporate website. For those unable to participate in the live session, a recorded replay will be accessible following the event. # # # About Stellantis Stellantis...

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s partnership-enabled business model Mr. Cleary previously served as Senior Vice President (“SVP”) of Corporate Development at Medtronic plc (NYSE: MDT) (“Medtronic”), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation (“AVIM”) therapy in hypertension with increased cardiovascular risk Eric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expertise and guidance to Orchestra BioMedNEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq:...

Modified intent-to-treat group demonstrated +22.7 point (p

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing...

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) — Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide. The award highlights Systemic Bio’s proprietary h-VIOS™ platform, designed to accelerate drug discovery and development using bioprinted human tissues. The Company’s presentation focused on the application of its platform to evaluate the safety of antibody-drug conjugates (ADCs). The technology enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical...

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,”...

Fourth Quarter 2024 HighlightsRevenue of $3.9 billion, a decrease of 1.3% as organic growth declined 0.5%; Organic growth of 0.4% turned positive excluding Product Line Simplification (PLS) reduction of 0.9% Record operating margin of 26.2%, an increase of 140 bps as enterprise initiatives contributed 120 bps Operating cash flow of $1.1B; record free cash flow of $1B, an increase of 10% with a conversion of 133% GAAP EPS of $2.54, an increase of 7%2024 HighlightsRevenue of $15.9 billion, a decrease of 1.3% as organic growth declined 0.7% in markets that were down low to mid-single digits Record operating margin of 26.8% as enterprise initiatives contributed 130 bps Record GAAP EPS of $11.71, an increase of 20%2025 GuidanceAbove-market organic growth of 0 to 2% based on current levels of demand; Organic growth of 1 to 3% excluding...